Xuezhou Zhang

2 Anzhen Road, Chaoyang District
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Response to Letter to the Editor: Comment on "Anticancer Drugs Associated With Tumor Lysis Syndrome: Insights From the US Food and Drug Administration Adverse Event Reporting System".

Response to Letter to the Editor: Comment on "Anticancer Drugs Associated With Tumor Lysis Syndrome: Insights From the US Food and Drug Administration Adverse Event Reporting System".

Journal: Clinical therapeutics

Published: May 08, 2026

Low-renin primary aldosteronism predicts superior surgical outcomes compared to high-renin disease.

Low-renin primary aldosteronism predicts superior surgical outcomes compared to high-renin disease.

Journal: BMC urology

Published: June 05, 2025

Establishment and evaluation of a patient-derived organoids-based xenograft model of primary aldosteronism using [18F]AlF-NOTA-pentixather PET/CT: bridging preclinical and clinical imaging.

Establishment and evaluation of a patient-derived organoids-based xenograft model of primary aldosteronism using [18F]AlF-NOTA-pentixather PET/CT: bridging preclinical and clinical imaging.

Journal: Journal of translational medicine

Published: May 21, 2025

Anticancer Drugs Associated With Tumor Lysis Syndrome: Insights From the US Food and Drug Administration Adverse Event Reporting System.

Anticancer Drugs Associated With Tumor Lysis Syndrome: Insights From the US Food and Drug Administration Adverse Event Reporting System.

Journal: Clinical therapeutics

Published: April 27, 2025

Primary aldosteronism patients with bilateral adrenal vein sampling success achieve better outcomes through unilateral adrenalectomy.

Primary aldosteronism patients with bilateral adrenal vein sampling success achieve better outcomes through unilateral adrenalectomy.

Journal: Translational andrology and urology

Published: February 06, 2025

Comprehensive pan-cancer analysis reveals CD70 as a promising therapeutic target and biomarker in clear cell renal cell carcinoma.

Comprehensive pan-cancer analysis reveals CD70 as a promising therapeutic target and biomarker in clear cell renal cell carcinoma.

Journal: International journal of biological macromolecules

Published: January 13, 2025

Circadian Rhythm Genes-based Prognostic Signature for Bladder Cancer: Association of EZH2 Expression with Anesthetic-related Changes in Circulating Tumor Cells.

Circadian Rhythm Genes-based Prognostic Signature for Bladder Cancer: Association of EZH2 Expression with Anesthetic-related Changes in Circulating Tumor Cells.

Journal: Current medicinal chemistry

Published: October 24, 2024

Frequent gene mutations and the correlations with clinicopathological features in clear cell renal cell carcinoma: preliminary study based on Chinese population and TCGA database.

Frequent gene mutations and the correlations with clinicopathological features in clear cell renal cell carcinoma: preliminary study based on Chinese population and TCGA database.

Journal: BMC urology

Published: June 28, 2024

Disulfidptosis and ferroptosis related genes define the immune microenvironment and NUBPL serves as a potential biomarker for predicting prognosis and immunotherapy response in bladder cancer.

Disulfidptosis and ferroptosis related genes define the immune microenvironment and NUBPL serves as a potential biomarker for predicting prognosis and immunotherapy response in bladder cancer.

Journal: Heliyon

Published: May 28, 2024

Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer.

Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer.

Journal: BMC cancer

Published: February 02, 2024

Development and validation of a circulating tumor cells-related signature focusing on biochemical recurrence and immunotherapy response in prostate cancer.

Development and validation of a circulating tumor cells-related signature focusing on biochemical recurrence and immunotherapy response in prostate cancer.

Journal: Heliyon

Published: July 31, 2023

Exploring the Potential Driver Gene Mutations That Promote Renal Cancer Cell Metastasis and Implantation Based on Circulating Tumor Cells Culture.

Exploring the Potential Driver Gene Mutations That Promote Renal Cancer Cell Metastasis and Implantation Based on Circulating Tumor Cells Culture.

Journal: Diagnostics (Basel, Switzerland)

Published: April 13, 2023

Showing 1-12 of 12

Last Updated: 09/26/2026